Immunohistochemical analyses of additional 296 PDA cases demonstrated that ARID1A protein deficiency was significantly associated with poor outcome in this expanded cohort (Fig. 3c, Supplementary Table 2). This evidence concerns the gene ARID1A and Patent ductus arteriosus.